Who
Michael J. Higgins
Director
Company insider
Files Form 4 as: Interim President & CEO, Voyager Therapeutics; Director, CAMP4 Therapeutics; Director, Cyclerion Therapeutics; Director, Pulmatrix; Director, Genocea Biosciences; Chief Operating Officer, Ironwood Pharmaceuticals.
In numbers
- Trades disclosed
- 68
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $5.0M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 2 Feb 2010
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | CAMP CAMP4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 25 Mar 2025filed 27 Mar 2025 | Cyclerion TherapeuticsBiotechnology | SEC FORM 4 Code A | $25K9,090 at $2.75 | filing |
| 5 Jun 2024filed 7 Jun 2024 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 6 Jun 2023filed 7 Jun 2023 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,436 at $0.00 | filing |
| 14 Jul 2022filed 18 Jul 2022 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $93K13,891 at $6.70 | filing |
| 6 Jun 2022filed 8 Jun 2022 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 27 Jan 2022filed 31 Jan 2022 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,833 at $0.00 | filing |
| 13 Jan 2022filed 18 Jan 2022 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —161,000 at $0.00 | filing |
| 13 Jan 2022filed 18 Jan 2022 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —45,205 at $0.00 | filing |
| 1 Jul 2021filed 2 Jul 2021 | Genocea Biosciencesoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Jun 2021filed 4 Jun 2021 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 28 Jan 2021filed 1 Feb 2021 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 18 Jun 2020filed 19 Jun 2020 | Genocea Biosciencesoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 4 Jun 2020filed 5 Jun 2020 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 21 Apr 2020filed 23 Apr 2020 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 2 Apr 2020filed 6 Apr 2020 | PULM Pulmatrixoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.